This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Teaneck, NJ, Cognizant Technology Solutions Corporation is a leading professional services company. The company was spun off from Dun & Bradstreet in 1996 and went public in 1998. Cognizant’s services include digital services and solutions, consulting, application development, systems integration, application testing, application maintenance, infrastructure services, and business process services. Cognizant reported revenues of $16.78 billion in 2019. Revenues from clients added during 2019, including those related to acquisitions were $234 million.
Cognizant (CTSH) Misses on Q1 Earnings, Cuts 2019 Guidance
by Zacks Equity Research
Cognizant Technology Solutions (CTSH) first-quarter 2019 results hurt by sluggish performance of Financial Services and Healthcare segments.
Cognizant (CTSH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cognizant (CTSH) delivered earnings and revenue surprises of -11.65% and -1.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cognizant (CTSH) This Earnings Season?
by Zacks Equity Research
Cognizant's (CTSH) first-quarter 2019 results are likely to benefit from domain expertise and acquisitions that are adding new customers.
Analysts Estimate Cognizant (CTSH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cognizant (CTSH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Value Investors Consider Cognizant Technology (CTSH)?
by Zacks Equity Research
Cognizant Technology (CTSH) stock may be a good choice for value-oriented investors right now from multiple angles.
CTSH or TYL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTSH vs. TYL: Which Stock Is the Better Value Option?
Outlook for Business-Software Services Stocks Appears Bright
by Madhura Bhattacharyya
The Zacks Business-Software Services industry is gaining traction from a strong demand environment for multi cloud-enabled software solutions.
Why Is Cognizant (CTSH) Down 0.9% Since Last Earnings Report?
by Zacks Equity Research
Cognizant (CTSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cognizant Acquires Meritsoft, Strengthens SaaS Portfolio
by Zacks Equity Research
Cognizant's (CTSH) acquisition of Meritsoft not only strengthens the former's software-as-a-Service (SaaS) portfolio but also expands its footprint among financial institutions.
Cognizant (CTSH) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Cognizant's (CTSH) fourth-quarter 2018 results benefit from growth across all four domains.
Cognizant (CTSH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cognizant (CTSH) delivered earnings and revenue surprises of 7.62% and 0.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Cognizant (CTSH) Q4 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Cognizant's (CTSH) fourth-quarter results are likely to be hurt by banking weakness despite gains from solid domain expertise and acquisitions that are adding new customers.
Cognizant (CTSH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cognizant (CTSH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Cognizant (CTSH) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cognizant (CTSH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Accenture Rides on Buyouts & Cloud, Pricing Pressure Rife
by Zacks Equity Research
While acquisitions increase Accenture's (ACN) revenue opportunities along with business mix and profitability, stiff completion leads to pricing pressure.
Accenture Boosts Financial Services With Orbium Buyout
by Zacks Equity Research
The acquisition is likely to boost Accenture's (ACN) Financial Services segment and enhance its global presence in terms of Avaloq execution.
Why Is Cognizant (CTSH) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Cognizant (CTSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accenture Completes Kaplan Buyout, Boosts Nordics Presence
by Zacks Equity Research
The acquisition of Kaplan is a part of Accenture (ACN) Interactive's bid to boost Nordics presence.
The Zacks Analyst Blog Highlights: Walmart, Cognizant, Vale, Church & Dwight and Ball
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Cognizant, Vale, Church & Dwight and Ball
Top Stock Reports for Walmart, Cognizant & Vale
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Walmart (WMT), Cognizant (CTSH) and Vale (VALE).
Cognizant (CTSH) Beats on Q3 Earnings, Revenues Increase Y/Y
by Zacks Equity Research
Cognizant's (CTSH) third-quarter 2018 results benefit from growth across all four domains.
Cognizant (CTSH) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Cognizant (CTSH) delivered earnings and revenue surprises of 5.31% and -0.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Cognizant (CTSH) in Q3 Earnings?
by Zacks Equity Research
Cognizant's (CTSH) third-quarter results are likely to benefit from domain expertise and acquisitions that are adding new customers.
Cognizant (CTSH) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Cognizant (CTSH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransUnion Inks Deal to Buy Rubixis, Boosts Healthcare Suite
by Zacks Equity Research
The deal to acquire Rubixis is expected to boost TransUnion (TRU) Healthcare's portfolio.